ESC 365 - AG10, an orally available, novel transthyretin (TTR) stabilizer: integrated preclinical evaluation predicts a highly effective treatment for TTR amyloid cardiomyopathy

ESC Premium Access

AG10, an orally available, novel transthyretin (TTR) stabilizer: integrated preclinical evaluation predicts a highly effective treatment for TTR amyloid cardiomyopathy

Session: Cardiac amyloidosis

Topic: Cardiomyopathies

Speaker: Associate Professor M. Alhamadsheh (Stockton, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Associate Professor Mamoun Alhamadsheh

University of the Pacific, Stockton (United States of America)

0 follower

6 more presentations in this session

Comparison of various non-invasive tools for diagnosing AL cardiac amyloidosis.

Speaker: Mr M. Nicol (Paris, FR)

Investigation of left ventricular function and biomarkers following treatment in patients with light-chain cardiac amyloidosis

Predictors of progression of light-chain cardiac amyloidosis.

Speaker: Doctor V. Rameev (Moscow, RU)

Prognosis of patients with cardiac amyloidosis referred in the French cardiac amyloidosis expert center.

Speaker: Professor T. Damy (Creteil, FR)

Long-term evolution of longitudinal myocardial deformation in the natural history of familial amyloid polyneuropathy

Speaker: Doctor G. Lima Da Silva (Lisbon, PT)

Access the full session

Cardiac amyloidosis

Speakers: Associate Professor M. Alhamadsheh, Mr M. Nicol, Doctor V. Rameev, Professor T. Damy, Doctor G. Lima Da Silva

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources